Multibagger Selection: DeepSeek's picks
DeepSeek picked QMLS, DUOT, TLSI, NUAI, OPTX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | QMLS | — | 82% | — | — |
| 2 | DUOT | — | 78% | — | — |
| 3 | TLSI | — | 74% | — | — |
| 4 | NUAI | — | 70% | — | — |
| 5 | OPTX | — | 68% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -0.02% | -0.54% | 1.25x | 0 |
| 1 month | -34.86% | -33.89% | 1.35x | 0 |
The model's market view
The small and mid-cap multibagger environment is selective but constructive. AI infrastructure, defense-space, and medical-device micro-caps with verifiable revenue inflection and specific catalysts are attracting capital, while speculative stories without near-term revenue visibility are being de-rated. Falling oil prices and easing bond-market stress are supportive for risk assets, but market breadth remains narrow. The most asymmetric opportunities sit in companies with market caps between $200M and $1B that have just crossed an operating inflection, have contracted backlog or regulatory clearance in hand, and trade at valuations that do not yet reflect the forward revenue run-rate. Balance-sheet survivability and dilution risk remain the key differentiators between genuine multibagger setups and value traps.
Why each pick
QMLS
QumulusAI is a neocloud infrastructure provider purpose-built for the AI computing era, trading at a market cap of approximately $228M. Revenue more than doubled year-over-year in Q2 2026 to $6.7M, gross margin expanded to 66.6% from 55.1%, and cumulative signed customer contract value reached $282.5M. The company guided to approximately $300M in forward ARR by year-end 2026, backed by 18 MW of data-center capacity, representing roughly 30x ARR growth over fiscal 2025. This is a company that has just crossed the inflection from pre-revenue infrastructure buildout to revenue-generating GPU capacity. The valuation is not cheap on trailing metrics, but the forward ARR trajectory makes the current market cap appear small relative to the contracted revenue pipeline. Deferred revenue rose $30.5M in the first half, contributing to $22.3M of operating cash flow, which materially reduces the dilution risk that typically plagues early-stage AI infrastructure companies.
DUOT
Duos Technologies has completed a full pivot from its legacy railroad-inspection business to AI data-center infrastructure. The Q2 2026 report was the first full quarter reflecting the new business, and the market reaction was strongly positive: revenue rose 30% YoY to $6.18M, gross margin expanded to 55.8% from 37.3%, and the company posted its first positive operating quarter. Duos now has more than 75 MW of data-center capacity under contract, driven by a deepening partnership with Axe Compute, including a five-year, 55 MW hosting agreement valued at more than $500M. The balance sheet is a genuine strength with $112.3M in cash and little debt, providing flexibility to fund expansion without emergency dilution. Management reaffirmed guidance of more than $50M in revenue for 2026 and early projections point to at least $160M in 2027.
TLSI
TriSalus Life Sciences is an oncology company integrating novel drug-delivery technology with standard-of-care therapies. The company received FDA 510(k) clearance for its TriNav Advance device on 2026-09-22, expanding its Pressure-Enabled Drug Delivery portfolio into smaller blood vessels that are difficult for doctors to reach. TriSalus has three FDA-cleared devices using the PEDD technology and is targeting a limited market release of TriNav Advance in the coming weeks. Revenue guidance for 2026 is $54-57M, representing growth of 19-26% over full-year 2025, and the company reiterated this guidance as recently as August 2026. The FDA clearance is a near-term commercial catalyst that broadens the addressable procedure base and supports the revenue trajectory.
NUAI
New Era Energy & Digital is a Texas data-center developer that signed a 20-year power purchase agreement with Luminant, a subsidiary of Vistra, on 2026-09-21. The agreement covers a minimum of 200 MW and up to 207 MW of power for Phase 1 of the company's Texas Critical Data Center project, with firm contracted power expected to begin in Q3 2027. The stock has surged more than 60% over the past month as the broader neocloud trade gains momentum, and the PPA is a major de-risking event because it secures long-term power supply for the data-center development. Revenue is still minimal at $1.36M TTM, but the PPA and the data-center development represent a substantial forward revenue opportunity.
OPTX
Syntec Optics is a deep-tech optics manufacturer serving defense, space, and AI data-center markets. The company secured its most critical order in its 25-year history on 2026-09-21, an order to build optics for U.S. Space Force government satellite constellations and advanced reconnaissance operations. The order was announced as a monumental milestone, though the exact value was not disclosed. Syntec has already built thousands of special laser connections for satellite-to-satellite communication and is positioned as a key supplier for government space infrastructure. Revenue in Q2 2026 reached an all-time high of $8.3M, up 26% YoY, with communications revenue up 74% and defense up 36%.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | INBX, CRML, LUNR, RDW, SRZN |
| Gemini 1.5 Pro | DLO, TBN, IRON, AGYS, VNDA |
| Muse Spark 1.1 | ENVA, SMR, RARE, CAPR, INDP |
| Perplexity | LQDA, AAOI, CRDO, RDW, POET |
| Grok 4.5 | AESI, SOUN, PRME, MYRG, VSEC |
| GPT-5.6 Sol | CAPR, NTLA, BEAM, LUNR, RXRX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.